

**REMARKS**


After entry of this paper claims 1-24, and 33-53 are pending. Claims 46-53 are new. The disclosure supports the new and amended claims and the amendments thus add no new matter. Support for the new claims is found  
5 throughout the disclosure with exemplary support as follows. Support for new claims 46-50 and 53 is at least at page 88, lines 11-22 and page 326, lines 29-34 (R<sup>4</sup> moieties, e.g., -NH<sub>2</sub> or ester, and their configurations), page 53, line 32, through page 54, line 5 (hydrogen atom configurations), page 326, lines 11-16 (R<sup>1</sup> moieties, e.g., -OH, and their configurations) and page 163, lines 23-24  
10 (amide and carbamate protecting groups). Support for new claim 51 is at least at page 327, lines 27-29 (subject is a mammal). Support for new claim 52 is at least at original claim 6 (neutropenia).

**RESTRICTION REQUIREMENT**

15 The Office issued a restriction requirement and required Applicants to select a disclosed species for examination. Applicants hereby elect the species that new claim 53 recites, i.e., treatment of neutropenia using the compound 3 $\beta$ -hydroxy-17 $\beta$ -aminoandrost-5-ene. Claims 1, 6, 7, 9-11, 13, 14 and 46-53 read on this species. Applicants' response fully complies with the restriction and election  
20 and an examination of the elected invention on the merits is respectfully requested. Applicants' representative can be reached at the number given below if the Office has any questions or would like to address any other matters that may arise.

Respectfully submitted,

25  
Dated: 12-15-03

  
Daryl D. Muenchau, Reg. No. 36,616  
Hollis-Eden Pharmaceuticals, Inc.  
4435 Eastgate Mall, Suite 400  
San Diego, CA 92121  
(P): 858-320-2569; (Fax): 858-558-6470